Feed BPTH
BP

Bio-Path Holdings, Inc.

BPTH · OTC

$0.00 +100.00% (+$0.00)
1M -99.48%
Market Cap $934.0
P/E Ratio -
Div. Yield -
ROE -

Bulios Fair Price

$0

100.0% downside

Trenutna cena

$0.0002

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica BPTH trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
1/9
Valuation
-
N/A
EV/EBITDA N/A
P/S N/A
P/B N/A
Growth
-
N/A
Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
-
N/A
Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
55 /100
Average
ROA 68,850.00%
Asset turnover 0.00x
ROIC 19.25%
Debt
0 /100
High
Int. coverage -9.55x
Current ratio 0.00x
Net debt/EBITDA N/A
Stability
40 /100
Moderate
EPS volatility 40.48%
Profitable years 0
Beta -0.53x

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o BPTH
Online

O podjetju

Bio-Path Holdings, Inc. (BPTH) is a biopharmaceutical company focused on developing drug candidates for the treatment of various types of cancer. Its main therapeutic platform includes liposomal delivery technology, which enables targeted delivery of therapeutic agents directly to cancer cells. The company primarily focuses on treating leukemia and various types of carcinomas, including breast, pancreatic, and lung cancers. Bio-Path Holdings conducts clinical trials and research to assess the efficacy of its drug candidates and their potential therapeutic benefits. Shares of Bio-Path Holdings, Inc. (BPTH) may be suitable for investors seeking opportunities in the biotechnology sector with a focus on innovative approaches to combating cancer.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Vikram Paul Grover

Employees

1

Headquarters

Bellaire

Prihajajoči dogodki

12 NOV.

Earnings

Upcoming earnings report

52d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.